Circulating monocytes and late in-stent restenosis: Reply  by Fukuda, Daiju et al.
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circulating Monocytes
nd Late In-Stent Restenosis
e read with great interest the study by Fukuda et al. (1)
hat evaluated the relationship between white blood cells in
eripheral blood and in-stent neointimal volume at six-
onth follow-up. The investigators demonstrated increased
irculating monocyte numbers after coronary stent implan-
ation and found the peak monocyte count related to
n-stent neointimal hyperplasia. These exciting findings are
trongly supported by several experimental studies, as out-
ined in the corresponding editorial (2), and add another
iece of evidence to the concept that apparently not mural
mooth muscle cells but other cell types play a more central
ole in neointima formation.
Given the diversity of peripheral blood leucocyte sub-
opulations, the exact identity of neointima-associated leu-
ocytes deserves careful consideration. In this context, we
ecently identified dendritic cells as novel neointimal cell
ype and demonstrated their maximal presence during early
eointima formation after rat carotid balloon injury (3. In
nother study, we also showed bone marrow-derived and
eural crest-derived cells within human in-stent restenosis
therectomy samples. Herein, dendritic cells constituted the
ajor mononuclear lesional cell type, whereas monocytes/
acrophages were confined to areas adjacent to stent struts
4). It is tempting to speculate that dendritic cells of the
eripheral blood, possibly included in the monocyte frac-
ion, may have been the key player in lesion formation in the
tudy of Fukuda et al. (1). Because C-reactive protein
CRP) had been shown to have chemotactic effects on
onocytes/macrophages (5) and to increase neointimal
ormation (6), we also would like to suggest that further
tudies on in-stent restenosis should elucidate specific sub-
opulations of the monocyte/macrophage lineage and the
ole of CRP.
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e greatly appreciate the interest and thoughtful comments
f Bauriedel et al. on our report (1) concerning the rela-
ionship between circulating monocytes and late in-stent
estenosis. As Bauriedel et al. commented, we consider that
ur results are supported by several experimental studies (2).
urthermore, we believe that our report raised an issue on
he contribution of monocytes, including smooth muscle
rogenitor cells, to neointimal formation in human stented
esions. There is increasing evidence that smooth muscle
rogenitors play an important roll in neointimal hyperplasia.
ata et al. (3) have demonstrated that circulating smooth
uscle progenitor cells significantly contribute to neointi-
al hyperplasia in several models of atherosclerosis. Con-
istently, it was reported that smooth muscle-like cells with
pecific growth, adhesion, and integrin profiles could out-
row from human peripheral mononuclear cells (4). In
umans, it is difficult to precisely investigate the cellularity
f in-stent plaque and its origin. A number of studies have
ttempted to elucidate the lineage of progenitors; however,
hey remain unidentified. In addition, these cells are
hought to contain a lot of lineages and be heterogeneous.
In-stent restenosis is different from typical atherosclerosis
ecause of its plaque composition and rapid progression. As
auriedel et al. (5,6) described in their work, there is the
ossibility that innate immunity cells relate to neointimal
ormation. In addition, these data are useful for understand-
ng the mechanism of in-stent restenosis. Furthermore,
everal inflammatory agents have been demonstrated to
elate to in-stent restenosis. We have demonstrated that not
nly plasma C-reactive protein levels but also in-stent
estenosis are associated with ruptured plaques that may
losely associate with inflammatory cells like monocytes
7,8). Therefore, there is possibility that these agents may
ave influences on mobilization and differentiation of
mooth muscle progenitors.
At any rate, it is plausible that circulating monocytes
ontribute to in-stent restenosis. Identifying neointima-
ssociated cells is important to know the mechanism of
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August 18, 2004:936–40n-stent restenosis, and we think that further investigations
re needed.
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rognostic Value of Left Ventricular
yssynchrony in Patients With Heart Failure
ader et al. (1) in a recent issue of the Journal reported on
he value of left ventricular (LV) dyssynchrony for the
rognostification of patients with severe heart failure (HF).
large group of HF patients (n  104) with depressed
eft ventricular ejection fraction (LVEF) (45%) was fol-
owed up for one year. During this one-year period, 83% of
he patients were hospitalized for decompensated HF.
ased on multivariate Cox regression analysis, three vari-
bles predicted HF hospitalization: QRS width 140 ms,
VEF 25%, and LV dyssynchrony (the mean LV dyssyn-
hrony was 68 44 ms). The patients included in the study
y Bader et al. (1) represent typical patients who may benefit
rom cardiac resynchronization therapy (CRT). Recent
tudies on CRT have shown improvement in symptoms,
uality-of-life score, exercise capacity, and LV systolic
unction after CRT (2). Current selection criteria for CRT dnclude: severe HF (New York Heart Association functional
lass III or IV), depressed LVEF (35%), and wide QRS
omplex (120 ms). Careful analysis of the large clinical
rials, however, has revealed that 20% to 30% of patients do
ot respond to CRT. Based on these observations, emphasis
as shifted toward a better selection of patients who may
enefit from CRT (3). Various studies have demonstrated
hat LV dyssynchrony may predict response to CRT and,
herefore, the findings of Bader et al. (1) are of great
mportance. Eventually, the identification of patients with
yssynchrony may not only allow for optimal selection for
RT but also may favorably affect the prognosis of these
atients. On the basis of their findings, do the authors feel
hat the presence of dyssynchrony should be used to identify
atients who may benefit from CRT? And, if so, should the
egion of latest activation before CRT be the preferred
ocation for the LV lead? This is of interest because
ubstantial percentage of patients in the study by Bader et al.
1) exhibited other regions than the lateral wall as the latest
ctivation. This may then in turn raise the question whether
surgical approach may sometimes be preferred rather than
ransvenous implantation of the LV lead.
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e thank Dr. Bax and colleagues for their interest in our
tudy (1) and, above all, for raising several important issues.
s they mentioned in their letter, various studies have
emonstrated or at least suggested that left ventricular (LV)
yssynchrony might predict response to cardiac resynchro-
ization therapy (CRT). A recent study published in the
ournal (2) has showed that patients with a narrow QRS
omplex and with LV electromechanical dyssynchrony
ould benefit from CRT (even with a larger pacing-induced
RS width compared with spontaneous rhythm) at the
ame level of hemodynamic and clinical improvement than
atients with large QRS complexes (120 ms). These new
ata can at least suggest that, independent of the QRS
